Provided by Tiger Trade Technology Pte. Ltd.

SINOMAB BIO-B

1.670
-0.020-1.18%
Volume:4.93M
Turnover:8.11M
Market Cap:2.32B
PE:-9.68
High:1.690
Open:1.690
Low:1.610
Close:1.690
52wk High:3.760
52wk Low:1.050
Shares:1.39B
HK Float Shares:1.39B
Volume Ratio:1.84
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.172
ROE:-55.49%
ROA:-9.91%
PB:8.37
PE(LYR):-9.68
PS:355.49

Loading ...

BRIEF-Sinomab Bioscience Posts Loss For Year Rmb105.0 Million

Reuters
·
Yesterday

SINOMAB BIO-B (03681) Reports Significant Narrowing of Losses in 2025, Major Strides in Pipeline Development and Commercialization

Stock News
·
Yesterday

SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million

Reuters
·
Yesterday

SinoMab reports SM17 Phase 1b atopic dermatitis results with 91.7% NRS-4 response rate

Reuters
·
Yesterday

Subsidiary of SINOMAB BIO-B (03681) Terminates Lease Agreement

Stock News
·
Mar 12

SinoMab BioScience - Termination of Lease Agreement Between Unit and Haikou Pharmaceutical Factory

THOMSON REUTERS
·
Mar 12

SinoMab BioScience terminates 20-year lease for Haikou Industry Park property

Reuters
·
Mar 12

SINOMAB BIO-B (03681.HK) Schedules 23 March 2026 Board Meeting to Approve FY2025 Final Results

Bulletin Express
·
Mar 10

SinoMab BioScience to Hold Board Meeting to Approve Full-Year Results

Reuters
·
Mar 10

SINOMAB BIO-B (03681) Announces Monthly Return for February 2026

Bulletin Express
·
Mar 05

SINOMAB BIO-B Shares Climb Over 5% in Morning Session; Phase II Trial for SM17 in Atopic Dermatitis Expected to Start in Q2

Stock News
·
Feb 25

SINOMAB BIO-B Receives NMPA Clearance for SM17 IBD Clinical Trial Application

Stock News
·
Feb 24

SinoMab BioScience Limited (3681) Announces IND Approval for SM17 in IBD

Bulletin Express
·
Feb 24

China NMPA approves SinoMab SM17 IND for inflammatory bowel disease

Reuters
·
Feb 24

SINOMAB BIO-B Shares Surge Over 5% Again as SM17 Preclinical Study Shows Strong Potential for CRSwNP and IPF Treatment

Stock News
·
Feb 20

No Products Secured Billion-Dollar Orders, Qiang Jing's Wife Cashed Out Before Sinovant's IPO

Deep News
·
Jan 05

Major IPO Update: Former CICC Research MD Leads Suzhou InnovaBio's Rapid Listing Acceptance on STAR Market

Deep News
·
Dec 24, 2025

BRIEF-Sinomab Bioscience Says IND Application For SM17 Accepted By NMPA CDE

Reuters
·
Dec 11, 2025

SinoMab BioScience Inflammatory Bowel Disease Drug Application Accepted in China

MT Newswires Live
·
Dec 11, 2025

SINOMAB BIO-B (03681): SM17 New Drug Research Application Accepted by NMPA's CDE

Stock News
·
Dec 11, 2025